DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RESCRIPTOR
All Clinical Trials for Rescriptor
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002210 | A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies | Completed | Pharmacia and Upjohn | Phase 2 | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs. |
| NCT00002211 | Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients | Completed | Pharmacia and Upjohn | N/A | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give combinations of three or four anti-HIV drugs to HIV-infected patients. The drugs used in this study are delavirdine (DLV), nelfinavir (NLF), didanosine (ddI), and stavudine (d4T). |
| NCT00002400 | A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients | Completed | Pharmacia and Upjohn | N/A | 1969-12-31 | The purpose of this study is to compare the safety and effectiveness of giving HIV-infected patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is given in combination with other drugs. |
| NCT00002401 | A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients | Completed | Pharmacia and Upjohn | N/A | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in combination with two or three other drugs to HIV-infected patients. The drugs to be used in combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC). |
| NCT00002420 | The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors | Terminated | Pharmacia and Upjohn | Phase 2 | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients. |
| NCT00002420 | The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors | Terminated | Triangle Pharmaceuticals | Phase 2 | 1969-12-31 | The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Rescriptor
Condition Name
Clinical Trial Locations for Rescriptor
Trials by Country
Clinical Trial Progress for Rescriptor
Clinical Trial Phase
Clinical Trial Sponsors for Rescriptor
Sponsor Name
